<SEC-DOCUMENT>0001129928-19-000029-index.html : 20190503
<SEC-HEADER>0001129928-19-000029.hdr.sgml : 20190503
<ACCEPTANCE-DATETIME>20190503103551
ACCESSION NUMBER:		0001129928-19-000029
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190503
DATE AS OF CHANGE:		20190503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		19794585

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q12019form6-k.htm
<DESCRIPTION>2019 FIRST QUARTER 6-K
<TEXT>
Document 1 - file: q12019form6-k.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>ex991-interimfsmar312019.htm <DESCRIPTION>2019 FIRST QUARTER INTERIM FINANCIAL STATEMENTS <TEXT> Document 2 - file: ex991-interimfsmar312019.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>ex992-q12019mda.htm <DESCRIPTION>2019 FIRST QUARTER MD&A <TEXT> Document 3 - file: ex992-q12019mda.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>4 <FILENAME>ex993-q12019certificationx.htm <DESCRIPTION>Q1 2019 CERTIFICATION CEO <TEXT> Document 4 - file: ex993-q12019certificationx.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.4 <SEQUENCE>5 <FILENAME>ex994-q12019certificationx.htm <DESCRIPTION>Q1 2019 CERTIFICATION CFO <TEXT> Document 5 - file: ex994-q12019certificationx.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>oncolyticslogobluea04.jpg <TEXT> Document 6 - file: oncolyticslogobluea04.jpg
</DOCUMENT> </SEC-DOCUMENT>